Mobilization of hematopoietic stem cells by plerixafor alone in children: A sequential Bayesian trial

Transfusion and Apheresis Science

Volumn 49, Issue 3, 2013, Pages 453-458

  Chambon, Fanny ^a,b,c   Merlin, Etienne ^a,b   Rochette, Emmanuelle ^a,b   Pereira, Bruno ^a   Halle, Pascale ^a   Deméocq, François ^a,b,c   Kanold, Justyna ^a,b,c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Apheresis; CXCR4 antagonist; Transplantation

Indexed keywords

PLERIXAFOR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; APHERESIS; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; INFANT; MALE; MONOTHERAPY; NEWBORN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; STEM CELL MOBILIZATION;

APHERESIS; CXCR4 ANTAGONIST; TRANSPLANTATION;

ADOLESCENT; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES;

EID: 84888433885     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.02.041     Document Type: Article

References (26)

1. Hartmann O., Vassal G., Valteau D., Brugières L., Lemerle J. Autologous bone marrow transplantation in pediatric solid tumors: phase II studies. Bone Marrow Transplant 1991, 7(Suppl. 3):106-108.
2. Ladenstein R., Treuner J., Koscielniak E., d'Oleire F., Keim M., Gadner H., et al. Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer 1993, 71:3647-3655.
3. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. N Engl J Med 1999, 341:1165-1173.
4. Demirer T., Bensinger W.I., Buckner C.D. Peripheral blood stem cell mobilization for high-dose chemotherapy. J Hematother 1999, 8:103-113.
5. Siena S., Schiavo R., Pedrazzoli P., Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000, 18:1360-1377.
6. Kanold J., Rapatel C., Berger M., Chassagne J., Lutz P., de Lumley L., et al. Use of G-CSF alone to mobilize peripheral blood stem cells for collection from children. Br J Haematol 1994, 88:633-635.
7. Liles W.C., Rodger E., Broxmeyer H.E., Dehner C., Badel K., Calandra G., et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
8. Berger M., Kanold J., Rapatel C., de Lumley L., Lutz P., Plantaz D., et al. Feasibility of a PB CD34+ cell transplantation procedure using standard leukapheresis products in very small children. Bone Marrow Transplant 1997, 20:191-198.
9. Deméocq F., Kanold J., Chassagne J., Bezou M.J., Lutz P., de Lumley L., et al. Successful blood stem cell collection and transplant in children weighing less than 25kg. Bone Marrow Transplant 1994, 13:43-50.
10. Zohar S., Teramukai S., Zhou Y. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. Contemp Clin Trials 2008, 29:608-616.
11. Berry D.A. Monitoring accumulating data in a clinical trial. Biometrics 1989, 45:1197-1211.
12. Zohar S., Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med 2001, 20:2827-2843.
13. Devine S.M., Vij R., Rettig M., Todt L., McGlauchlen K., Fisher N., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
14. Flomenberg N., Comenzo R.L., Badel K., Calandra G. Plerixafor (mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant 2010, 16:695-700.
15. Devine S.M., Flomenberg N., Vesole D.H., Liesveld J., Weisdorf D., Badel K., et al. Rapid mobilization of cd34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:1095-1102.
16. Merlin E., Piguet C., Auvrignon A., Rubie H., Deméocq F., Kanold J. The pros and cons of split-dose granulocyte colony-stimulating factor alone rather than a single high dose for hematopoietic progenitor cell mobilization in small children (<15kg) with solid tumors. Haematologica 2006, 91:1004-1005.
17. Sevilla J., González-Vicent M., Madero L., García-Sánchez F., Díaz M.A. Granulocyte colony-stimulating factor alone at 12μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant 2002, 30:417-420.
18. Pérez-Dueñas B., Alcorta I., Estella J., Rives S., Toll T., Tuset E. Safety and efficacy of high-dose G-CSF (24μg/kg) alone for PBSC mobilization in children. Bone Marrow Transplant 2002, 30:987-988.
19. Avramova B.E., Yordanova M.N., Konstantinov D.N., Bobev D.G. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (mozobil) and granulocyte-colony stimulating factor. Drug Des Dev Ther 2011, 5:407-409.
20. Hübel K., Fresen M.M., Salwender H., Basara N., Beier R., Theurich S., et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011, 46:1045-1052.
21. Sevilla J., Schiavello E., Madero L., Pardeo M., Guggiari E., Baragaño M., et al. Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment. J Pediatr Hematol Oncol 2012, 34:146-150.
22. Aabideen K., Anoop P., Ethell M.E., Potter M.N. The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. J Pediatr Hematol Oncol 2011, 33:65-67.
23. Stewart D.A., Smith C., MacFarland R., Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009, 15:39-46.
24. Choi H., Yong C., Yoo B.K. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother 2010, 44:117-126.
25. Lemery S.J., Hsieh M.M., Smith A., Rao S., Khuu H.M., Theresa D., et al. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol 2011, 153:66-75.
26. Cardenoux C., Deméocq F., Kanold J., Merlin E., Oudot C., Piguet C., et al. Pegfilgrastim plus AMD 3100 for stem-cell mobilization in children. Pediatr Blood Cancer 2010, 55:769.